左卡尼汀对非酒精性脂肪肝的疗效观察  

Clinical efficacy of levocarnitine in the treatment of non-alcoholic fatty liver

作　　者：游云鹏[1] 郑大东[1] 王颖[1] 钟勇[1] 潘士勇[1] 

机构地区：[1]南京军区南京总医院干部保健科,南京210002

出　　处：《医学研究生学报》2015年第8期847-849,共3页Journal of Medical Postgraduates

摘　　要：目的非酒精性脂肪肝(Nonalcoholic fatty liver,NAFL)是一种代谢性疾病,左卡尼汀具有改善机体代谢作用。文章旨在观察左卡尼汀治疗NAFL的疗效。方法回顾性收集2012年1月至2013年6月期间南京军区南京总医院门诊85例NAFL患者,并根据治疗方法的不同分为左卡尼汀组和对照组。左卡尼汀组(n=45)在生活方式干预的基础上应用左卡尼汀治疗4周,减量后继续治疗8周;对照组(n=40)仅给予生活方式干预。结果左卡尼汀治疗12周后,左卡尼汀组显效37例,无效8例,有效率82.2%;对照组显效25例,无效15例,有效率50.0%。2组有效率比较差异有统计学意义(P<0.01)。左卡尼汀组在治疗过程中未发生不良反应。结论在生活方式干预基础上应用左卡尼汀治疗非酒精性脂肪肝可提高治疗有效率。Objective Non-alcoholic fatty liver （NAFL） is a metabolic disease and levocarnitine can be used to improve the energy metabolism of the patient. This study aimed to evaluate the clinical efficacy of levocamitine in the treatment of NAFL. Methods We retrospectively analyzed 85 cases of NAFL treated by lifestyle intervention （control group, n =40） or by lifestyle intervention ＋ levo- carnitine medication （ medication group, n = 45）. In addition to lifestyle intervention, the patients in the medication group received oral levocarnitine at 10 mL tid for 4 weeks followed by a reduced dose of 10 mL bid for another 8 weeks. Results Twelve weeks after treat- ment, 37 cases （82.2%） in the medication group showed remarkable improvement and the other 8 failed to respond. In the control group, 23 cases （57.5%） were improved and 17 cases remained unimproved. There were statistically significant differences in the rate of therapeutic effectiveness between the two groups of patients （P 〈0.01 ）. No adverse effects were observed during the levocarnitine medi- cation. Conclusion Lifestyle intervention ＋ levocamitine medication can improve NAFL.

关 键 词：左卡尼汀 非酒精性脂肪肝 疗效 

分 类 号：R657.3[医药卫生—外科学]